Johnson & Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer

Johnson & Johnson to Acquire Auris Health for its Monarch Technology for $5.7B


  • J&J acquires TARIS Biomedical while TARIS to continue research in Lexington, Massachusetts and will also become part of Janssen R&D’s Oncology Therapeutic Area. Additionally, the companies will focus on optimization of drug candidates for advancing and delivering future clinical programs utilizing TARIS technology
  • The focus of an acquisition is to utilize TARIS’ drug delivery technology for advancing TAR-200 candidate further strengthening targeted oncologic therapy approach
  • TARIS’ TAR-200 is an investigational candidate designed to release chemotherapeutic agent gemcitabine continuously in bladder for multiple weeks and has also received FDA’s Fast Track Designation in patients with organ-confined or locally advanced MIBC who are unfit for curative-intent therapy

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox